Skip to content

Patient Priorities in the Management of Early Oesophageal Cancer: A Discrete Choice Study

Patient Priorities in the Management of Early Oesophageal Cancer: A Discrete Choice Study

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07828314
Enrollment
118
Registered
2026-09-18
Start date
2025-08-06
Completion date
2026-08-01
Last updated
2026-09-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Oesophageal Cancer

Brief summary

Understanding patient priorities is important to providing thorough, individualised care in oesophageal cancer. We aim to use questionnaires to explore what is important to patients when considering radical surgery for oesophageal cancer, and to analyse how patients interpret the risk explained to them during the consent process

Interventions

BEHAVIORALSemi-structured interview

Interviews will be facilitated by the research team. The sessions will be designed to follow the consolidated criteria for reporting qualitative research (COREQ) (12). The Questionnaire on Distress in Cancer Patients and The Cancer Worry Scale (both validated patient surveys) were also used to help design the script for the interview. The full interview script can be found in a separate document entitled "Patient priorities in Oesophageal Cancer".

Participants will be asked to imagine the following scenario; "You have undergone endoscopic resection for an early oesophageal cancer. All your cancer has been removed, but the histology from your endoscopic resection shows you are at an increased risk of recurrence. This risk could be reduced by undergoing a radical oesophagectomy. The following options are presented to you;" \- Questionnaire will involve choosing between 2 treatments options; Active surveillance or radical surgery. * 5 attributes will be assigned to each treatment option. Examples of possible attributes; 5-year survival (this pertains to risk of nodal/distant metastases) Risk of mortality from surgery Short-term HRQoL Long-term HRQoL Frequency of invasive tests * Each attribute will have 3 levels * It would not be possible to expose patients to all choice sets (\>200). Software will be used to design 20 choice sets that will make up the questionnaire.

Sponsors

Portsmouth Hospitals NHS Trust
Lead SponsorOTHER_GOV

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Under care of local MDT for monitoring/surveillance/treatment of Barretts/dysplasia/oesophageal cancer * able to communicate in English Language

Exclusion criteria

* Unable or unwilling to give informed consent

Design outcomes

Primary

MeasureTime frameDescription
Patient priorities6 monthsInterview responses and responses from discrete choice experiment.

Countries

United Kingdom

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 19, 2026